Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6.

Published on Jul 1, 2019in European Journal of Pharmaceutics and Biopharmaceutics4.604
· DOI :10.1016/J.EJPB.2019.05.008
Emma von Witting4
Estimated H-index: 4
(KTH: Royal Institute of Technology),
Javad Garousi13
Estimated H-index: 13
(Uppsala University)
+ 7 AuthorsVladimir Tolmachev61
Estimated H-index: 61
(Uppsala University)
Sources
Abstract
Abstract Radionuclide molecular imaging is a promising tool that becomes increasingly important as targeted cancer therapies are developed. To ensure an effective treatment, a molecular stratification of the cancer is a necessity. To accomplish this, visualization of cancer associated molecular abnormalities in vivo by molecular imaging is the method of choice. ADAPTs, a novel type of small protein scaffold, have been utilized to select and develop high affinity binders to different proteinaceous targets. One of these binders, ADAPT6 selectively interacts with human epidermal growth factor 2 (HER2) with low nanomolar affinity and can therefore be used for its in vivo visualization. Molecular design and optimization of labeled anti-HER2 ADAPT has been explored in several earlier studies, showing that small changes in the scaffold affect the biodistribution of the domain. In this study, we evaluate how the biodistribution properties of ADAPT6 is affected by the commonly used maleimido derivatives of the macrocyclic chelators NOTA, NODAGA, DOTA and DOTAGA with the aim to select the best variants for SPECT and PET imaging. The different conjugates were labeled with 111In for SPECT and 68Ga for PET. The acquired data show that the combination of a radionuclide and a chelator for its conjugation has a strong influence on the uptake of ADAPT6 in normal tissues and thereby gives a significant variation in tumor-to-organ ratios. Hence, it was concluded that the best variant for SPECT imaging is 111In-(HE)3DANS-ADAPT6-GSSC-DOTA while the best variant for PET imaging is 68Ga-(HE)3DANS-ADAPT6-GSSC-NODAGA.
📖 Papers frequently viewed together
9 Citations
10 Citations
2010
1 Author (Sara Ahlgren)
References38
Newest
#1Javad Garousi (Uppsala University)H-Index: 13
#2Sarah Lindbo (KTH: Royal Institute of Technology)H-Index: 8
Last. Sophia Hober (KTH: Royal Institute of Technology)H-Index: 41
view all 11 authors...
Abstract ADAPTs are small engineered non-immunoglobulin scaffold proteins, which have demonstrated very promising features as vectors for radionuclide tumour targeting. Radionuclide imaging of human epidermal growth factor 2 (HER2) expression in vivo might be used for stratification of patients for HER2-targeting therapies. ADAPT6, which specifically binds to HER2, has earlier been shown to have very promising features for in vivo targeting of HER2 expressing tumours. In this study we tested the...
11 CitationsSource
#1Maryam Oroujeni (Uppsala University)H-Index: 7
#2Javad Garousi (Uppsala University)H-Index: 13
Last. Vladimir Tolmachev (Uppsala University)H-Index: 61
view all 7 authors...
Radionuclide imaging of epidermal growth factor receptor (EGFR) expression in tumors may stratify patients for EGFR-targeting therapies and predict response or resistance to certain treatments. Affibody molecules, which are nonimmunoglobulin scaffold proteins, have a high potential as probes for molecular imaging. In this study, maleimido derivative of desferrioxamine B (DFO) chelator was site-specifically coupled to the C-terminal cysteine of the anti-EGFR affibody molecule ZEGFR:2377, and the ...
11 CitationsSource
#1Kelly E. Henry (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 4
#2Gary A. Ulaner (Cornell University)H-Index: 28
Last. Jason S. LewisH-Index: 87
view all 3 authors...
Breast cancer is the most common cancer in women worldwide, with approximately 12% of women in the United States developing invasive breast cancer in her lifetime.1 Although breast cancer has come a long way in regards to treatment options and overall survival, there are still challenges that occur mostly from intratumoral heterogeneity2 and metastatic disease.3 While significant research has emerged to identify biological processes leading to breast cancer,4 selecting patients that would benefi...
11 CitationsSource
#1Sarah Lindbo (KTH: Royal Institute of Technology)H-Index: 8
#2Javad Garousi (Uppsala University)H-Index: 13
Last. Vladimir Tolmachev (Uppsala University)H-Index: 61
view all 8 authors...
Radionuclide molecular imaging is a promising tool for visualization of cancer associated molecular abnormalities in vivo and stratification of patients for specific therapies. ADAPT is a new type of small engineered proteins based on the scaffold of an albumin binding domain of protein G. ADAPTs have been utilized to select and develop high affinity binders to different proteinaceous targets. ADAPT6 binds to human epidermal growth factor 2 (HER2) with low nanomolar affinity and can be used for ...
9 CitationsSource
#1Ahmet KrasniqiH-Index: 8
Last. Vladimir Tolmachev (Uppsala University)H-Index: 61
view all 8 authors...
Imaging of expression of therapeutic targets may enable patients' stratification for targeted treatments. The use of small radiolabeled probes based on the heavy-chain variable region of heavy-chai ...
55 CitationsSource
#1Dominik SummerH-Index: 10
#2Javad Garousi (Uppsala University)H-Index: 13
Last. Clemens DecristoforoH-Index: 53
view all 10 authors...
Zirconium-89 is an emerging radionuclide for positron emission tomography (PET) especially for biomolecules with slow e pharmacokinetics as due to its longer half-life, in comparison to fluorine 18 ...
20 CitationsSource
#1Sarah Lindbo (KTH: Royal Institute of Technology)H-Index: 8
#2Javad Garousi (Uppsala University)H-Index: 13
Last. Vladimir Tolmachev (Uppsala University)H-Index: 61
view all 8 authors...
Visualization of cancer-associated alterations of molecular phenotype using radionuclide imaging is a noninvasive approach to stratifying patients for targeted therapies. The engineered albumin-bin ...
24 CitationsSource
#1Javad Garousi (Uppsala University)H-Index: 13
#2Sarah Lindbo (KTH: Royal Institute of Technology)H-Index: 8
Last. Sophia Hober (KTH: Royal Institute of Technology)H-Index: 41
view all 8 authors...
ABD-Derived Affinity Proteins (ADAPTs) is a novel class of engineered scaffold proteins derived from an albumin-binding domain of protein G. The use of ADAPT6 derivatives as targeting moiety have p ...
9 CitationsSource
#1Javad Garousi (Uppsala University)H-Index: 13
#2Ken G. Andersson (KTH: Royal Institute of Technology)H-Index: 12
Last. Vladimir Tolmachev (Uppsala University)H-Index: 61
view all 11 authors...
Several anti-cancer therapies target the epidermal growth factor receptor (EGFR). Radionuclide imaging of EGFR expression in tumours may aid in selection of optimal cancer therapy. The 111In-labelled DOTA-conjugated ZEGFR:2377 Affibody molecule was successfully used for imaging of EGFR-expressing xenografts in mice. An optimal combination of radionuclide, chelator and targeting protein may further improve the contrast of radionuclide imaging. The aim of this study was to evaluate the targeting p...
25 CitationsSource
#1Véronique Diéras (Curie Institute)H-Index: 74
#2David Miles (NU: Northwood University)H-Index: 18
Last. Luca Gianni (UniSR: Vita-Salute San Raffaele University)H-Index: 85
view all 12 authors...
Summary Background The antibody–drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane. Approval of this drug was based on progression-free survival and interim overall survival data from the phase 3 EMILIA study. In this report, we present a descriptive analysis of the final overall survival data from that trial. Methods EMILIA was a randomised, international, open-label, phase ...
215 CitationsSource
Cited By7
Newest
#1Sergey Deyev (Tomsk Polytechnic University)H-Index: 2
#2Tianqi Xu (Uppsala University)H-Index: 2
Last. Torbjörn Gräslund (KTH: Royal Institute of Technology)H-Index: 21
view all 13 authors...
The epithelial cell adhesion molecule (EpCAM) is intensively overexpressed in 40–60% of prostate cancer (PCa) cases and can be used as a target for the delivery of drugs and toxins. The designed ankyrin repeat protein (DARPin) Ec1 has a high affinity to EpCAM (68 pM) and a small size (18 kDa). Radiolabeled Ec1 might be used as a companion diagnostic for the selection of PCa patients for therapy. The study aimed to investigate the influence of radiolabel position (N- or C-terminal) and compositio...
1 CitationsSource
#1Vladimir Tolmachev (Tomsk Polytechnic University)H-Index: 61
#2Anna Orlova (Tomsk Polytechnic University)H-Index: 53
Last. Jens Nørkær Sørensen (Uppsala University)H-Index: 66
view all 3 authors...
Abstract Targeting of human epidermal growth factor type 2 (HER2) using monoclonal antibodies, antibody-drug conjugates and tyrosine kinase inhibitors extends survival of patients with HER2-expressing metastatic breast cancer. High expression of HER2 is a predictive biomarker for such specific treatment. Accurate determination of HER2 expression level is necessary for stratification of patients to targeted therapy. Non-invasive in vivo radionuclide molecular imaging of HER2 has a potential of re...
1 CitationsSource
#1Emma Renard (University of Burgundy)H-Index: 1
#2Mathieu Moreau (University of Burgundy)H-Index: 10
Last. Victor Goncalves (University of Burgundy)H-Index: 14
view all 8 authors...
Neurotensin receptor 1 (NTS1) is involved in the development and progression of numerous cancers, which makes it an interesting target for the development of diagnostic and therapeutic agents. A small molecule NTS1 antagonist, named [177Lu]Lu-IPN01087, is currently evaluated in phase I/II clinical trials for the targeted therapy of neurotensin receptor-positive cancers. In this study, we synthesized seven compounds based on the structure of NTS1 antagonists, bearing different chelating agents, a...
Source
#1Javad Garousi (Uppsala University)H-Index: 13
#2Emma von Witting (KTH: Royal Institute of Technology)H-Index: 4
Last. Sophia Hober (KTH: Royal Institute of Technology)H-Index: 41
view all 11 authors...
Abstract Molecular recognition in targeted therapeutics is typically based on immunoglobulins. Development of engineered scaffold proteins (ESPs) has provided additional opportunities for the development of targeted therapies. ESPs offer inexpensive production in prokaryotic hosts, high stability and convenient approaches to modify their biodistribution. In this study, we demonstrated successful modification of the biodistribution of an ESP known as ADAPT (Albumin-binding domain Derived Affinity...
1 CitationsSource
#1Benjamin P. Burke (University of Hull)H-Index: 11
#2Stephen J. Archibald (University of Hull)H-Index: 25
1 CitationsSource
#1Anzhelika Vorobyeva (Uppsala University)H-Index: 11
#2Ekaterina Bezverkhniaia (Tomsk Polytechnic University)H-Index: 1
Last. Vladimir Tolmachev (Uppsala University)H-Index: 61
view all 10 authors...
Efficient treatment of disseminated triple-negative breast cancer (TNBC) remains an unmet clinical need. The epithelial cell adhesion molecule (EpCAM) is often overexpressed on the surface of TNBC cells, which makes EpCAM a potential therapeutic target. Radionuclide molecular imaging of EpCAM expression might permit selection of patients for EpCAM-targeting therapies. In this study, we evaluated a scaffold protein, designed ankyrin repeat protein (DARPin) Ec1, for imaging of EpCAM in TNBC. DARPi...
4 CitationsSource
#1Anzhelika VorobyevaH-Index: 11
#2Maryam OroujeniH-Index: 7
Last. Javad GarousiH-Index: 13
view all 8 authors...
Albumin binding domain-Derived Affinity ProTeins (ADAPTs) are small (5 kDa) engineered scaffold proteins that are promising targeting agents for radionuclide-based imaging. A recent clinical study has demonstrated that radiolabeled ADAPTs can efficiently visualize human epidermal growth factor receptor 2 (HER2) expression in breast cancer using SPECT imaging. However, the use of ADAPTs directly labeled with radiometals for targeted radionuclide therapy is limited by their high reabsorption and p...
1 CitationsSource